Get the SPI Wire

GALECTIN THERAPEUTICS INC.

NASDAQ:GALT
Annual Meeting

of Shareholders

MEETING DATE

12/03/2026
DEF 14A FILED
10/13/2026
PUBLISHED
10/13/2026 12:00 pm
TIME TO PUBLISH
10/15/2026
METHODOLOGY
approve
EXCHANGE NASDAQ:GALT · CUSIP 363225202 · CLASS Common Stock or Series A 12% Convertible Preferred Stock · CIK 0001133416

RECONCILED · MIXED

Reconciled against the company’s Form 8-K Item 5.07 filed 2026-06-15.

3
FOR
1
AGAINST
0
WITHHOLD
4
BALLOT ITEMS

ITEM-BY-ITEM RECOMMENDATIONS

1
To elect the eleven (11) nominees for director named in the accompanying proxy statement to hold office until the 2027 annual meeting of our stockholders.
board
Elevated
For
Board FOR · Duopoly unknown — No divergence flagged

The filing states each of the eleven nominees agreed to serve if elected.

Divergence: 0 Review status: Approved. Publication ledger and 8-K reconciliation pending.
2
To adopt and approve an amendment to our Restated Articles of Incorporation increasing the number of authorized common voting shares ("common stock") from 150,000,000 to 250,000,000.
other
Elevated
Against
Board FOR · Duopoly unknown — ⚠ Divergence flagged

The filing states additional issuances could dilute existing stockholders and may make obtaining control of the Company more difficult.

Divergence: 1 Review status: Approved. Publication ledger and 8-K reconciliation pending.
3
To approve an amendment to our 2019 Omnibus Equity Incentive Plan to reserve an additional 3,000,000 shares for issuance under the plan.
compensation
Elevated
For
Board FOR · Duopoly unknown — No divergence flagged

The Board approved an amendment to reserve 3,000,000 additional shares under the plan.

Divergence: 0 Review status: Approved. Publication ledger and 8-K reconciliation pending.
4
To ratify the selection by the Audit Committee of the Board of Directors of Cherry Bekaert LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.
auditor
Elevated
For
Board FOR · Duopoly unknown — No divergence flagged

The Audit Committee selected Cherry Bekaert LLP for the fiscal year ending December 31, 2026.

Divergence: 0 Review status: Approved. Publication ledger and 8-K reconciliation pending.

Ledger

6652118d8c07a1cfafbc5e8a95ee72b18f8b5036f8f5a57733e9d2437580b52e

Search company, ticker, executive, director or issue

    The SPI Wire · Proxy Intelligence

    Get every ballot call, before the vote.

    FOR, AGAINST or WITHHOLD on each covered ballot item — published within 48 hours of the definitive proxy filing. Follow the companies you own, or take the full feed.




    Pick the companies you own — you’ll only hear from us on their ballots.

    The SPI Wire covers proxy ballots only — it has nothing to do with Signal Research investigations. Research and analysis for informational purposes; not legal, investment, or voting advice. Unsubscribe anytime.

    Submit Information








      Join Monitoring List




        Receive Research Updates